Case reportInterleukin-1 blockade in refractory giant cell arteritis
Introduction
Glucocorticoids (GCs) remain the mainstay of treatment for giant cell arteritis (GCA). However, relapses are common when GC dosages are tapered, resulting in high cumulative doses with substantial GC-related toxicity and morbidity [1]. GCA patients refractory to GCs exhibit elevated tissue expression of the pro-inflammatory cytokines IL-1β, TNFα, and IL-6 [2] thus prompting investigators to use cytokine blockade therapy in this particular setting. TNF-blockers have failed to prove effectiveness and cannot therefore be recommended [3]. Recently, tocilizumab, an anti-IL-6 receptor therapy, has been suggested as a treatment option in refractory GCA patients [4]. However, randomized controlled trials are needed to confirm this finding. We hypothesized, on the basis of data from animal studies in which mice lacking the interleukin 1 receptor antagonist (IL-1ra) gene developed large vessel vasculitis [5], that IL-1 blockade with anakinra could be a therapeutic option in patients with GCA refractory to GCs and other steroid-sparing agents.
Section snippets
Case reports
The first patient (80-year-old male) presented in June 2005 with a 2-month history of fever of unknown origin, night sweats, weight loss and pain over his shoulder and pelvic girdle. Inflammation markers were elevated with a C-reactive protein (CRP) of 80 mg/L. A comprehensive workup including searches for an infectious disease and a whole-body CT-scan yielded normal or negative results. Temporal artery biopsy (TAB) only showed elastic internal lamina disruption. Gallium-67 scintigraphy
Discussion
Corticosteroids-sparing agents have a limited action in giant cell arteritis [6]. Methotrexate seems to show some efficacy [7]. TNF-blocking agents (infliximab and etanercept) have failed to induce and maintain disease remission [3], [8]. The efficacy of tocilizumab in naïve and refractory GCA patients has recently been demonstrated in several case series [4], [9], [10]. This anti-IL-6 receptor therapy is well tolerated in the short and medium period of treatment. However, its efficacy over a
Disclosure of interest
The authors declare that they have no conflicts of interest concerning this article.
Acknowledgements
We thank Dr Cornelia Wilson and Lisa Mouche for providing helpful suggestions to a previous version of the manuscript.
References (15)
Therapeutic approach to giant cell arteritis
Joint Bone Spine
(2012)- et al.
Efficacy of tocilizumab in refractory giant cell arteritis
Joint Bone Spine
(2012) - et al.
Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes
Arthritis Rheum
(2003) - et al.
Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis
Rheumatology
(2004) - et al.
Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial
Ann Intern Med
(2007) - et al.
Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series
Swiss Med Wkly
(2011) - et al.
Elastic-vessel arteritis in interleukin-1 receptor antagonist-deficient mice involves effector Th1 cells and requires interleukin-1 receptor
Circulation
(2005)
Cited by (71)
Vasculitis therapy refines vasculitis mechanistic classification
2021, Autoimmunity ReviewsCitation Excerpt :Seven articles contained data on overlapping study populations (RITUXVAS trial [17,18], RAVE trial [19–21] and MAINRITSAN trial [22,23]), but were all included. The qualitative synthesis included 20 RCTs [17–36], 16 prospective cohort studies [10,11,13,15,16,37–47], 1 retrospective cohort study [14] and 3 case series [12,48,49]. Patients in RCTs were treated with: avacopan [35], mepolizumab [34], tocilizumab [30,32,33], infliximab [25,26], etanercept [24,29], adalimumab [31], abatacept [27,28], rituximab [17–23,25] and belimumab [36].
Giant cell arteritis: From pathogenesis to new therapeutic targets
2020, Bulletin de l'Academie Nationale de MedecineReview of phase 2/3 trials in polymyalgia rheumatica and giant cell arteritis
2024, Expert Opinion on Emerging DrugsGiant cell arteritis and innovative treatments
2023, Current Opinion in Allergy and Clinical Immunology